Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis

BACKGROUND: This study aimed to analyze the effects of ruxolitinib on children with secondary hemophagocytic lymphohistiocytosis (HLH). METHODS: Eleven pediatric patients diagnosed with HLH and treated with ruxolitinib (ruxolitinib group: group R) between November 2017 and August 2018 were retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Ying, Liu, Rong, Zhou, Zhi-xuan, Shi, Xiao-dong, Ding, Yu-chuan, Li, Jian-guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015074/
https://www.ncbi.nlm.nih.gov/pubmed/33794928
http://dx.doi.org/10.1186/s12969-021-00534-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015074/
https://www.ncbi.nlm.nih.gov/pubmed/33794928
http://dx.doi.org/10.1186/s12969-021-00534-0

Ejemplares similares